Abstract
Epidemiological studies have long associated circadian rhythm disruption (CRD)—often caused by shift work or chronic jet lag—with an increased risk of breast cancer. However, the precise molecular mechanisms linking systemic clock desynchronization to mammary gland morphology and aggressive tumorigenesis have remained elusive. This study investigates the impact of CRD on basal-type breast cancer using a combination of genetically engineered mouse models (GEMM), single-cell RNA sequencing (scRNA-seq), and human patient data. We demonstrate that chronic CRD disrupts mammary gland development and accelerates the initiation and metastatic progression of Triple-Negative Breast Cancer (TNBC). Mechanistically, CRD induces an immunosuppressive tumor microenvironment (TME) by upregulating the inhibitory receptor LILRB4a. Targeted immunotherapy against LILRB4a was found to reverse CRD-induced immunosuppression and significantly reduce lung metastasis, identifying LILRB4a as a critical link between circadian health and cancer progression.
Introduction
The circadian clock is a fundamental biological system that regulates physiological processes over a 24-hour cycle. Chronic disruption of this cycle is a known risk factor for various malignancies, particularly breast cancer. While previous research has established a correlation, this study aims to define how CRD influences the physical structure of the mammary gland and the behavior of aggressive basal-type tumors. By mapping the transcriptomic landscape of the tumor microenvironment, we sought to identify targetable pathways that could mitigate the heightened cancer risks faced by populations with irregular sleep-wake cycles.
Methods
To simulate chronic circadian disruption, wild-type and transgenic mice were subjected to a "jet lag" model involving an 8-hour light phase advance every two days. The study utilized a GEMM that recapitulates human basal-type breast cancer and a 4T1 orthotopic transplant model to evaluate tumor initiation, growth, and metastasis.
Single-cell RNA sequencing (scRNA-seq) was performed on tumors from both control (LD 12:12) and CRD groups to identify changes in the immune and stromal cell populations. These findings were validated using multiplexed immunostaining, flow cytometry, and real-time PCR. Finally, the researchers cross-referenced mouse findings with human data from The Cancer Genome Atlas (TCGA) and existing TNBC single-cell datasets to establish clinical relevance.
Results
CRD and Mammary Morphology
Before the onset of tumorigenesis, chronic CRD was found to sabotage normal mammary gland development. Wild-type mice under CRD conditions exhibited decreased ductal branching and a significantly higher frequency of ductal hyperplasia. These morphological changes suggest that circadian disruption creates a pro-tumorigenic environment in healthy tissue long before a primary tumor is detectable.
Acceleration of Tumorigenesis and Metastasis
In the basal-type GEMM, CRD significantly accelerated tumor initiation, with tumors appearing at 18 weeks compared to 22 weeks in control mice. While the growth rate of established primary tumors showed only a modest increase, the impact on metastasis was profound. CRD mice displayed a significantly higher burden of metastatic foci in the lungs, indicating that circadian disruption primarily drives the early stages of cancer development and the subsequent systemic spread.
Remodeling the Tumor Microenvironment
ScRNA-seq revealed that CRD fundamentally rewires the TME into an immunosuppressive, or "cold," state. The analysis showed a significant increase in "suppressor" cell populations, including M2-macrophages, regulatory T-cells (Tregs), and myeloid-derived suppressor cells (MDSCs). Conversely, "attacker" populations—such as CD8+ T cells, M1-macrophages, and dendritic cells—were markedly decreased.
The LILRB4a Mechanism
The study identified the inhibitory immune receptor LILRB4a as the primary molecular driver of this immunosuppressive shift. LILRB4a expression was significantly upregulated in both the mammary glands and tumors of CRD-exposed mice. In human datasets, aggressive TNBCs showed higher "CRD scores" (indicating greater clock disruption) and lower expression of core clock genes (e.g., PER1, PER2, CRY1), which correlated with higher LILRB4 levels and poorer outcomes.
Therapeutic Intervention
To test the functional importance of this pathway, the researchers administered a targeted anti-LILRB4 immunotherapy. This treatment successfully reduced the population of immunosuppressive Tregs and significantly inhibited CRD-induced lung metastasis (P < 0.0001). These results suggest that blocking LILRB4 can reverse the immune evasion promoted by circadian disruption.
Discussion
This research establishes LILRB4a as a critical bridge between systemic circadian disruption and local immune suppression in the mammary gland. By turning the tumor microenvironment "cold," CRD allows aggressive basal-type cancers to initiate earlier and spread more effectively to the lungs.
While the study identifies LILRB4a as a potent target, the exact signaling pathway connecting core clock proteins (like BMAL1/CLOCK) to the activation of the Lilrb4 gene remains a subject for future investigation. Furthermore, while the anti-LILRB4 therapy showed efficacy in mouse models, clinical studies are required to determine its potential as a preventative or adjunct treatment for shift workers and others suffering from chronic circadian rhythm disruption. These findings underscore the importance of circadian health in cancer prevention and offer a promising new avenue for immunotherapeutic intervention in aggressive breast cancer subtypes.
Summary updated